Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H33NO4 |
| Molecular Weight | 327.4589 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCC\C(=C/CCCCCCCC(O)=O)[N+]([O-])=O
InChI
InChIKey=WRADPCFZZWXOTI-BMRADRMJSA-N
InChI=1S/C18H33NO4/c1-2-3-4-5-8-11-14-17(19(22)23)15-12-9-6-7-10-13-16-18(20)21/h15H,2-14,16H2,1H3,(H,20,21)/b17-15+
| Molecular Formula | C18H33NO4 |
| Molecular Weight | 327.4589 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:55:13 GMT 2023
by
admin
on
Sat Dec 16 01:55:13 GMT 2023
|
| Record UNII |
1N19AGY57Y
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
701019
Created by
admin on Sat Dec 16 01:55:13 GMT 2023 , Edited by admin on Sat Dec 16 01:55:13 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB15026
Created by
admin on Sat Dec 16 01:55:13 GMT 2023 , Edited by admin on Sat Dec 16 01:55:13 GMT 2023
|
PRIMARY | |||
|
1N19AGY57Y
Created by
admin on Sat Dec 16 01:55:13 GMT 2023 , Edited by admin on Sat Dec 16 01:55:13 GMT 2023
|
PRIMARY | |||
|
875685-46-4
Created by
admin on Sat Dec 16 01:55:13 GMT 2023 , Edited by admin on Sat Dec 16 01:55:13 GMT 2023
|
PRIMARY | |||
|
300000020411
Created by
admin on Sat Dec 16 01:55:13 GMT 2023 , Edited by admin on Sat Dec 16 01:55:13 GMT 2023
|
PRIMARY | |||
|
CXA-10
Created by
admin on Sat Dec 16 01:55:13 GMT 2023 , Edited by admin on Sat Dec 16 01:55:13 GMT 2023
|
PRIMARY | 10-Nitrooleate: Item NO. 10008043, CAS NO. 875685-46-4Description: Synonyms - (1)10-Nitrooleic Acid, (2)10-nitro-9-trans-Octadecenoic AcidNitrated unsaturated fatty acids, such as 10- and 12-nitrolinoleate (LNO2Item No. 10037), cholesteryl nitrolinoleate, and nitrohydroxylinoleate, represent a new class of endogenous lipid-derived signalling molecules. LNO2 isomers serve as potent endogenous ligands for PPAR.GAMMA. and can also decompose or be metabolized to release nitric oxide. 10-Nitrooleate is one of two regioisomers of nitrooleate, the other being 9-nitrooleate (Item No. 10008042) (OA-NO2, used for the mixture of isomers), which are formed by nitration of oleic acid in approximately equal proportions in vivo. Peroxynitrite, acidified nitrite, and myeloperoxidase in the presence of H2O2 and nitrite, all mediate the nitration of oleic acid. OA-NO2 is found in human plasma as the free acid and esterified in phospholipids at concentrations of 619 +/- 52 nM and 302 +/- 369 nM, respectively. OA-NO2 activates PPAR.GAMMA. approximately 7-fold at a concentration of 1 uM. and effectively promotes differentiation 3T3-L1 preadipocytes to adipocytes at 3 uM. | ||
|
24836820
Created by
admin on Sat Dec 16 01:55:13 GMT 2023 , Edited by admin on Sat Dec 16 01:55:13 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Complexa; Class: Nitro compound, Small molecule, Unsaturated fatty acid; Mechanism of Action: Inflammation mediator modulator, Signal transduction pathway modulator, Transcription factor modulator; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phase: Phase I for Acute kidney injury, Renal failure; Most Recent Events: 16 May 2016 Chemical information added, 12 Nov 2015 Complexa plans phase II trials for Focal segmental glomerulosclerosis (FSGS), Pulmonary arterial hypertension (PAH) and Sickle cell disease in USA, 12 Nov 2015 Complexa completes four phase I trials (NCT02127190, NCT02248051, NCT02460146, NCT02313064) in Acute kidney injury in USA
|
||
|
ACTIVE MOIETY |
Drugs: CXA 10(Primary), CXA 10(Primary); Indication: Sickle cell anaemia; Focus: Adverse reactions, Therapeutic Use; Most Recent Events: 20 Nov 2015 New trial record, 12 Nov 2015 According to Complexa media release, this trial will initiate trials 2016.
|
